Maxcyte vs Omniab
Maxcyte is the larger business, with $33.0m of revenue in fiscal 2025 against $18.7m for Omniab (1.8 times as much). Maxcyte grew faster (-14.5% against -29.3%). Maxcyte kept more of each dollar of sales as profit: a net margin of -135.1% against -347.0%. Maxcyte carries less debt relative to equity (0.0% against 0.0%).
| Latest fiscal year | MaxcyteMXCT, 2025 | OmniabOABI, 2025 |
|---|---|---|
| Revenue | $33.0m | $18.7m |
| Revenue growth | -14.5% | -29.3% |
| Net income | −$44.6m | −$64.8m |
| Operating margin | -157.1% | -369.5% |
| Net margin | -135.1% | -347.0% |
| Return on equity | -23.6% | -23.4% |
| Free cash flow | −$36.2m | −$37.0m |
| Cash | $20.1m | $25.5m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 91 | 89 |
| Market value | $150m | $736m |
| Price vs our value range | — | — |
| Moat score | 30 (Weak) | — |
| Insider trades, 12 months | 0 buys, 1 sales | 2 buys, 12 sales |